SecBot SecBot
PRESS-RELEASE ·Filed Nov 12, 2026

ANAB

AnaptysBio, Inc.
BEARISH
Impact 4/10
Horizonweeks Processed4d 9h ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ▼ Bearish

The revenue and EPS miss is significant, but the stock's reaction will likely be dominated by the binary catalysts ahead: the Quimilza PDUFA on Dec 12, 2026, and the GSK litigation judgment in Q4 2026/Q1 2027. A favorable litigation outcome (reversion of Jemperli rights) would be transformative; a loss would leave Anaptys as a pure royalty streamer. Monitor for any pre-PDUFA advisory committee meeting or settlement news.

DirectionBearish
Confidencehigh
Horizonweeks

Drug in focus

Jemperli

● Neutral Named in this press release
Impact
Phase
Approved (Phase 3 / registrational Phase 2 for additional indications)
Time to market
Already marketed (first FDA approval April 2021). Potential label expansion in dMMR/MSI-H rectal cancer would follow AZUR-1 data (H2 2026) and subsequent BLA filing.
Next catalyst
None dated

What to watchWatch for AZUR-1 Phase 2 registrational data in H2 2026, a positive readout (extending the 100% cCR rate seen in the MSK-collaboration study) could lead to an FDA filing for rectal cancer and support the ~$2.5B+ peak sales consensus. Be aware of the AnaptysBio royalty dispute going to trial in July 2026, which could alter Jemperli's economics. For a diversified phyla stock like GSK, Jemperli is a growth driver in oncology but not a stand-alone thesis.

How the stock moved after the report

⚠ Clustered BEARISH VIEWSTOCK BELOW ENTRY AT T+1
Entry
$46.25
T+0 close · Nov 12, 2026 · via day close
Latest settled
−1.12%
T+1 · $45.73
Vs SPY
+0.79%
α at T+1
Next horizon
T+5
in 3d
  1. T+0 · Nov 13 $46.25entry
  2. T+1 · 20h ago −1.12%α +0.79% · $45.73
  3. T+5 · in 3d Pending
  4. T+20 · in 27d Pending
  5. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

AnaptysBio reported Q1 FY2027 (Sep 2026) collaboration revenue of $30.3M, below the $33.5M consensus, and GAAP EPS of $0.13, well below the $0.53 consensus estimate. The revenue decline was driven by the absence of a $50M milestone recognized in the year-ago quarter, partially offset by higher Jemperli royalties. The company highlighted the upcoming PDUFA date for Quimilza (Dec 12, 2026) and the pending litigation judgment against GSK/Tesaro (Q4 2026 or Q1 2027) as key catalysts.

Key Financial Metrics

EPS
$0.11
est $0.53 · -79.3%
Revenue
$30.3M
est $33.5M · -9.6% · -60.3% YoY
Rating
miss

Key Facts

  • Collaboration revenue of $30.3M for Q1 FY2027 (Sep 2026), down from $76.3M in the year-ago quarter, missing the $33.5M consensus.
  • GAAP net income from continuing operations of $3.9M ($0.13 per diluted share), down from $56.3M ($1.94 per diluted share) in Q1 FY2026, missing the $0.53 consensus EPS estimate.
  • Cash and investments totaled $153.0M at Sep 30, 2026, down from $164.1M at Jun 30, 2026.
  • Jemperli global net sales reached $1.0B for the nine months ended Sep 30, 2026, up 29% YoY; Anaptys receives 12% royalties on net sales between $1.0B and $1.5B annually.
  • FDA target action date (PDUFA) of December 12, 2026, for Quimilza in generalized pustular psoriasis (GPP).
  • Post-trial hearing in GSK/Tesaro litigation held Oct 20, 2026; judgment anticipated in Q4 2026 or Q1 2027.

Financial Impact

Revenue miss of ~$3.2M (10% below consensus) and EPS miss of $0.40 (75% below consensus) for the quarter. Cash burn of $11.1M in the quarter.

revenueepscash

Risk Factors

  • Revenue and EPS materially below consensus for the quarter.
  • GSK litigation outcome is binary and uncertain; a loss would severely limit upside.
  • Quimilza PDUFA in December 2026 is a binary regulatory event with no guarantee of approval.
  • Cash burn continues; $153M cash provides limited runway if no milestone or royalty payments materialize.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
93% bullish (15 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3402246

Track record

28 reports on ANAB

Performance horizon

9 of 18 bullish or bearish reports moved the stock their way by T+1. Best: +41.26% at T+60 after the Mar 3, 2026 report. 12 of 18 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $46.25 Now $45.73 −1.12% settles Nov 17
  2. Nov 12, 20264d ago Press Release Bearish 4/10 Viewing Entry $46.25 to $45.73 Now $45.73 +1.12% ▲ +1.12% −0.79% vs SPY
  3. Nov 6, 202610d ago Institutional Cluster Neutral 2/10 Entry $46.45 to $47.97 Now $45.73 −1.55% ▲ +3.27% +0.91% vs SPY
  4. Sep 21, 20268w ago Press Release Neutral 5/10 Entry $53.92 to $50.77 Now $45.73 −15.19% ▼ −5.84% −5.12% vs SPY
  5. Aug 12, 202613w ago Institutional Cluster Bullish 5/10 Entry $56.02 to $58.47 Now $45.73 −18.37% ▲ +4.37% +4.57% vs SPY
  6. Jun 29, 202620w ago 144 Bearish 6/10 Entry $67.50 to $65.43 Now $45.73 +32.25% ▲ +3.07% +2.93% vs SPY
  7. Jun 29, 202620w ago DEFA14A Neutral 2/10 Entry $67.50 to $65.43 Now $45.73 −32.25% ▼ −3.07% −2.93% vs SPY
  8. Jun 26, 202620w ago 144 Bearish 6/10 Entry $65.97 to $67.50 Now $45.73 +30.68% ▼ −2.32% −1.54% vs SPY
  9. Jun 22, 202621w ago 8-K Neutral 2/10 Entry $59.43 to $58.48 Now $45.73 −23.05% ▼ −1.60% −1.55% vs SPY
  10. Jun 17, 202621w ago 144 Bearish 5/10 Entry $57.51 to $59.99 Now $45.73 +20.48% ▼ −4.31% −4.63% vs SPY
Showing 10 of 28

US Market Status

Market Closed · Opens in 6h 41m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 12, 2026